New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
OverviewChart

Quote Panel

Shape
Updated April 26, 2025
1W 1.55 % 1M -10.86 % 3M -23.94 % 1Y -55.13 %

Key Metrics

Shape

  • Market Cap

    5.09M

  • Shares Outstanding

    2.59M

  • Share in Float

    2.53M

  • Dividende

    0

  • Earning Date

    09 May 2025

  • Price Target

    1.97

  • Average Volume

    128214

  • Beta

    4.636

  • Range

    1.69-6.9

  • Industry

    Biotechnology

  • Website

    https://www.creativemedicaltechnology.com

  • Sector

    Healthcare

Fundamentals

Shape

Relative Strength

Shape

CELZ

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$600K

Shape19900%

2025-Revenue

$2.03

Shape-62%

2025-EPS

$600K

Shape68%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Roth Capital

initialise

Previous: Not converted

2022-02-25

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q1.23

arrow
arrow

N/A

-0.70
vs -0.18

Q2.23

arrow
arrow

N/A

-0.78
vs -0.20

Q3.23

arrow
arrow

N/A

-1.02
vs -0.07

Q4.23

arrow
arrow

N/A

-1.21
vs -0.53

Q1.24

arrow
arrow

N/A

-0.73
vs -0.70

Q2.24

arrow
arrow

N/A

-1.11
vs -0.78

Q3.24

arrow
arrow

N/A

-0.75
vs -1.02

Q4.24

arrow
arrow

N/A

-1.12
vs -1.21

Q1.25

arrow
arrow

N/A

-0.64
vs -0.73

Q2.25

arrow
arrow

N/A

-0.54
vs -1.11

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+450%

55K  vs 10K

Q4.22

arrow
arrow

-73%

18.6K  vs 67.8K

Q1.23

arrow
arrow

-100%

NA  vs 15K

Q2.23

arrow
arrow

-100%

NA  vs 10K

Q3.23

arrow
arrow

-89%

6K  vs 55K

Q4.23

arrow
arrow

-84%

3K  vs 18.6K

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

8K  vs NA

Q3.24

arrow
arrow

-100%

NA  vs 6K

Q4.24

arrow
arrow

NA

3K  vs 3K

Return on EquityShape

status-upQoQ

Q1.23

arrow
arrow

-7%

-0.07
vs -0.39

Q2.23

arrow
arrow

-8%

-0.08
vs -0.07

Q3.23

arrow
arrow

-12%

-0.12
vs -0.08

Q4.23

arrow
arrow

-16%

-0.16
vs -0.12

Q1.24

arrow
arrow

-11%

-0.11
vs -0.16

Q2.24

arrow
arrow

-20%

-0.20
vs -0.11

Q3.24

arrow
arrow

-16%

-0.16
vs -0.20

Q4.24

arrow
arrow

-29%

-0.29
vs -0.16

Institutionnal OwnershipShape

status-upQoQ

Q4.21

arrow
arrow

1

1
vs NA

NA

Earnings Growth

Latest News

CELZ

globenewswire.com

7 hours ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
CELZ

globenewswire.com

7 hours ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™
CELZ

globenewswire.com

8 hours ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds
CELZ

globenewswire.com

9 hours ago

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
CELZ

zacks.com

10 hours ago

Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year?
CELZ

zacks.com

13 hours ago

Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock?